Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP)

Prostate

Volumn 67, Issue 2, 2007, Pages 178-189

  Koochekpour, Shahriar ^a,b   Lee, Tae Jin ^a   Wang, Ruoxiang ^c   Culig, Zoran ^d   Delorme, Nathalie ^a   Caffey, Soren ^a   Marrero, Luis ^a   Aguirre, Jennifer ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

AR; Prosaposin; Prostate cancer; PSA; Saposin C

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROSAPOSIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B INHIBITOR; SAPOSIN C; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROGEN-BINDING PROTEIN; ANILIDES; CELL LINE, TUMOR; CELL NUCLEUS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MALE; PLASMIDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAPOSINS; TRANSFECTION; UP-REGULATION;

EID: 33846640478     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20513     Document Type: Article

References (37)

1. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr Relat Cancer 2002;9:61-73.
2. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2:389-396.
3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
4. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-3555.
5. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-285.
6. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002;197:231-238.
7. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-1697.
8. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001;7:2941-2948.
9. Kishimoto Y, Hiraiwa M, O'Brien JS. Saposins: Structure, function, distribution and molecular genetics. J Lipid Res 1992;33:1255-1267.
10. Campana WM, Hiraiwa M, O'Brien JS. Prosaptide activates the MAPK pathway by a G protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J 1998;3:307-314.
11. Hiraiwa M, Taylor EM, Campana WM, Darin SJ, O'Brien JS. Cell death prevention, mitogen-activated protein kinase stimulation, and increased sulfatide concentration in Schwann cells and oligodendrocytes by prosaposin and prosaptides. Proc Natl Acad Sci USA 1997;94:4778-4781.
12. Kotani Y, Matsuda S, Wen T-C, Sakanaka M, Tanaka J, Maeda N, Kondoh K, Ueno S, Sano A. A hydrophilic peptide comprising 18 amino acid residues of prosaposin sequence has neurotrophic activity in vitro and in vivo. J Neurochem 1996;66:2197-2200.
13. Hiraiwa M, Campana WM, Martin BM, O'Brien JS. Prosaposin receptor: Evidence for a G-protein associated receptor. Biochem Biophys Res Commun 1997;240:415-418.
14. Koochekpour S, Sartor O, Lee T-J, Zieske A, Patten DY, Hiraiwa M, Sandhoff K, Remmel N, Minokdeh A. Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells. Prostate 2004;61:114-123.
15. Fujita N, Suzuki K, Vanier MT, Popko B, Maeda N, Klein A, Henseler M, Sandhoff K, Nakayasu H, Suzuki K. Targeted disruption of the mouse sphingolipid activator gene: A complex phenotype, including sever leukodystrophy and wide-spread storage of multiple sphingolipids. Human Mol Genetic 1996;5:711-725.
16. Elleder M, Jerabkova M, Befekadu A, Hrebicek M, Berna L, Ledvinova J, Hulkova H, Rosewich H, Schymik N, Paton BC, Harzer K. 2005. Prosaposin deficiency - a rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. Neuropediatrics 2005;36:171-180.
17. Morales CR, Zhao Q, El-Alfy M, Suzuki K. Targeted disruption of the mouse prosaposin gene affects the development of the prostate gland and other male reproductive organs. J Androl 2000;21:765-775.
18. Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W, Remmel N, Sandhoff K, Minokadeh A, Patten DY. Saposin C stimulates growth and invasion, activates p42/44 and SAPK/ JNK signaling pathways of MAPK and Upregulates uPA/uPAR expression in prostate cancer and stromal cells. Asian J Androl 2005;7:147-158.
19. Lee T-J, Sartor O, Luftig R, Koochekpour S. 2004. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells. Mol Cancer 2004;3:31.
20. Koochekpour S, Zhuang Y-J, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Patten DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 2005;44:351-364.
21. Henseler M, Klein A, Glombitza GJ, Suziki K, Sandhoff K. Expression of the three alternative forms of the sphingolipid activator protein precursor in baby hamster kidney cells and functional assays in a cell culture system. J Biol Chem 1996;271:8416-8423.
22. Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande
23. Woude GF. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-5912.
24. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, Hebert FE, Kao YS, Skinner J, Rayford W. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 2004;60:141-152.
25. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002;277:29304-29314.
26. O'Malley BW, Tsai SY, Bagchi M, Weigel NL, Schrader WT, Tsai MJ. Molecular mechanism of action of a steroid hormone receptor. Recent Prog Horm. Res 1991;47:1-24.
27. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol 2004;167:469-478.
28. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 2003;162:233-241.
29. Litvinov IV, Chang C, Isaacs JT. Molecular characterization of the commonly used human androgen receptor expression vector, pSG5-AR. Prostate 2004;58:319-324.
30. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 2000;275:40846-40855.
31. Culig Z, Hobisch A, Bartsch G, Klocker H. Androgen receptor-an update of mechanisms of action in prostate cancer. Urol Res 2000;28:211-219.
32. Kuiper GG, Brinkmann AO. Phosphotryptic peptide analysis of the human androgen receptor: Detection of a hormone-induced phosphopeptide. Biochemistry 1995;34:1851-1857.
33. Cato AC, Henderson D, Ponta H. The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. EMBO J 1987;6:363-368.
34. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-283.
35. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocrin Rev 2004;25:276-308.
36. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271:19900-19907.
37. Culig Z, Hobisch A, Cronauer MV, Raymayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.